Praluent mechanism of action
Pro Research Analysisby 
Searched over 200M research papers
Praluent Mechanism of Action
Introduction to Praluent (Alirocumab)
Praluent, also known by its generic name alirocumab, is a fully human monoclonal antibody developed by Regeneron Pharmaceuticals and Sanofi. It has been approved for use in the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease who require additional lowering of low-density lipoprotein cholesterol (LDL-C) .
PCSK9 Inhibition Mechanism
Targeting PCSK9
Praluent works by specifically binding to proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that plays a crucial role in cholesterol metabolism by downregulating liver LDL receptors. These receptors are responsible for removing LDL-C from the bloodstream. By inhibiting PCSK9, Praluent increases the number of available LDL receptors on the liver cells, thereby enhancing the liver's ability to clear LDL-C from the blood 12.
Administration and Efficacy
Praluent is administered via subcutaneous injection every two weeks. Clinical trials have demonstrated that alirocumab significantly reduces LDL-C levels in patients with both familial and nonfamilial hypercholesterolemia. This reduction is observed whether Praluent is used as monotherapy or in combination with statin therapy. Additionally, it has shown efficacy in patients with mixed dyslipidemia and those with statin intolerance .
Clinical Impact and Benefits
LDL-C Reduction
Across multiple phase III studies, Praluent has been shown to be more effective in reducing LDL-C levels over 24 weeks compared to placebo, ezetimibe, or modified statin therapy. The LDL-C-lowering effect of Praluent is sustained over longer treatment periods of 52 to 78 weeks .
Additional Lipid Parameters
Besides lowering LDL-C, Praluent also has favorable effects on other lipid parameters, including non-high-density lipoprotein cholesterol (non-HDL-C) and lipoprotein (a) [Lp(a)]. This broad spectrum of lipid-lowering effects makes Praluent a valuable option for patients with hypercholesterolemia, especially those who are statin-intolerant or have inadequately controlled LDL-C levels despite statin therapy .
Safety Profile
Praluent has been generally well tolerated in clinical trials, with no significant increase in muscle-related adverse events compared to placebo. This favorable safety profile further supports its use in a broader patient population .
Conclusion
Praluent (alirocumab) represents a significant advancement in the treatment of hypercholesterolemia through its novel mechanism of action as a PCSK9 inhibitor. By increasing the liver's ability to clear LDL-C from the blood, Praluent offers an effective and well-tolerated option for patients needing additional LDL-C reduction, particularly those with statin intolerance or inadequately controlled cholesterol levels.
Sources and full results
Most relevant research papers on this topic